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Oswaldo Cruz, Salvador, Brazil, 4 Parasite Genomics, Wellcome Trust Sanger Institute, Cambridge, United Kingdom,
5 Instituto de Ciẽncias Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Brazil, 6 York Structural Biology
Laboratory, University of York, York, United Kingdom
The radiation-attenuated cercarial vaccine remains the gold standard for the induction of
protective immunity against Schistosoma mansoni. Furthermore, the protection can be
passively transferred to naïve recipient mice from multiply vaccinated donors, especially
IFNgR KO mice. We have used such sera versus day 28 infection serum, to screen
peptide arrays and identify likely epitopes that mediate the protection. The arrays
encompassed 55 secreted or exposed proteins from the alimentary tract and
tegument, the principal interfaces with the host bloodstream. The proteins were
printed onto glass slides as overlapping 15mer peptides, reacted with primary and
secondary antibodies, and reactive regions detected using an Agilent array scanner.
Pep Slide Analyzer software provided a numerical value above background for each
peptide from which an aggregate score could be derived for a putative epitope. The
reactive regions of 26 proteins were mapped onto crystal structures using the CCP4
molecular graphics, to aid selection of peptides with the greatest accessibility and
reactivity, prioritizing vaccine over infection serum. A further eight MEG proteins were
mapped to regions conserved between family members. The result is a list of priority
peptides from 44 proteins for further investigation in multiepitope vaccine constructs
and as targets of monoclonal antibodies.
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INTRODUCTION
The production of a schistosome vaccine would be a valuable
addition to the toolbox of measures currently being used to
control and ultimately to eradicate schistosomiasis, but decades
of research towards that goal have yielded only a meagre harvest.
The first human vaccine trial, with ShGST (1) ended with an
inconclusive outcome while at least three other single antigen
formulations are in early Phases of trials (2). Against this
background, the vaccination of rodents and primates with
Radiation-Attenuated (RA) cercariae remains a well-established
means of inducing specific acquired immunity. By judicious
manipulation of adjuvants (e.g. IL-12) it is possible to drive
protection towards high levels (3, 4), although sterile immunity
has never been achieved. Only Smp80 calpain has come
anywhere near to emulating the protection achieved by the RA
vaccine (5). Schistosomes undergo a protracted migration from
the skin infection site to the hepatic portal system, entirely in the
bloodstream, with one to several circuits of the vasculature (6). In
mice only ~32% of penetrant cercariae reach maturity, while in
primates >80% may mature (7). The lungs are a particular
obstacle to migration and the difference in maturation has
been attributed to the relative fragility of lung capillaries. The
effect of the RA vaccine is to amplify the probability of migrating
schistosomula getting stuck in the lungs on each pass (P ~ 0.36 in
a naive mouse; P ~ 0.53 with 40% protection; P ~ 0.72 with 70%
protection). Much has been discovered about the underlying
immunology (8, 9). Inflammatory foci form around the larvae as
they make strenuous efforts to traverse the capillary beds,
impeding their progress and even deflecting them into alveoli
(10). In contrast, there is little concrete information about the
nature of the mediating antigens emanating from the live
schistosomula targets (11).
Beginning in the 1980s, strenuous efforts were made to
characterize the composition and antigenicity of the
schistosome tegument, as a major parasite interface with the
host, and potential target of immune attack. Techniques included
biosynthetic labeling with 35S methionine and iodination of
surface proteins, linked to immunoprecipitation and separation
of proteins on 1D and 2D gels (12). Isolated membranes of the
adult worm tegument (13) were also used to probe both human
(14) and rodent (15) responses to schistosome infection, using
western blotting. These approaches identified many reactivities,
and clear differences were observed between infection and
vaccination serum (12). However, at the time there was no
simple and direct way to establish the identities of targets; this
proceeded by isolation of one protein at a time, e.g., the Sm200
tegument surface protein (16). Rapid and comprehensive
identification of proteins on gels and blots had to wait for the
availability of a large transcriptome database (17), which
facilitated the application of proteomics to schistosomes (18),
especially to tegument proteins (19, 20). The biosynthetic radio-
labeling approach applied to schistosomula revealed a
characteristic pattern of proteins secreted during culture to the
lung stage (21) but the dominant band was only identified by
proteomics 17 years later, as a mixture of micro exon gene
(MEG)-3 family proteins (22); the origin of these proteins in the
head gland and tegument was confirmed by in situ hybridization
(23). However, other secreted proteins of the migrating
schistosomulum (21) remain to be identified directly by
proteomics and can only be inferred from transcript data
(24, 25).
Two new approaches, systems biology analysis and epitope
mapping with peptide arrays have recently emerged as tools to
aid in vaccine development. Systems biology was first applied to
the mechanisms underlying vaccine-induced immunity in
infections as diverse as yellow fever, influenza and malaria
(26–29) and we have recently used it to analyze the immune
processes associated with the RA schistosome vaccine in mice
(30). We found that the failure to deploy the normal mechanisms
for downregulation of hemostasis and coagulation after
vaccination may explain parasite blockade in the lungs. Genes
encoding chemokines and their receptors were also more
prominent in vaccinated mice, indicating an enhanced capacity
for inflammation. Both changes could potentially impact on
intravascular migration. Epitope mapping has been made
feasible by the laser-printing of overlapping 15mer peptides
covering target protein sequences onto glass slides for
screening with immune sera (https://www.pepperprint.com/).
The approach has been used to identify epitopes in infectious
agents as diverse as viruses, bacteria, protozoa and helminths
(31–34). Recently, the technology was applied to map the
epitopes present in 32 S. japonicum esophageal gland proteins
using macaque, rabbit and mouse sera, and identified a
significant number of immunodominant sequences for
incorporation into vaccine constructs (35). The current report
is a companion study to the systems biology analysis (30) using
sera generated from vaccinated and infected C57Bl/6 mice,
supplemented by high titer serum from IFNgR KO mice (36),
to screen peptide arrays for reactivity to 55 secreted and surface-
exposed proteins of S. mansoni. We mapped the reactive regions
of 26 array proteins onto 3D crystal structure homologues, and
for eight MEG proteins lacking solved crystal structures, to
conserved regions. This has enabled the selection of a panel of
epitopes, based on rational criteria, for incorporation into multi-




The mouse sera for array screening came from Instituto
Butantan, Sao Paulo, Brazil (C57Bl/6) and University of York,
York, UK (IFNgR KOmice). Both were derived from or based on
previously described research (30, 36, 37). Brazil procedures were
conducted in strict accordance with good practices as defined by
the Committee for the Ethical Use of Animals in
Experimentation of the Butantan Institute (São Paulo, Brazil)
under license 1030/13. York procedures were carried out in
accordance with the UK Animals (Scientific Procedures) Act
1986, authorized on personal and project licenses to RAW and
PSC, issued by the UK Home Office. The study protocol was
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approved by the Biology Department Ethical Review Committee
at the University of York.
Details of Sera
C57Bl/6 mice: Full details of the experiments can be found in
(30). Vaccination serum (V) came from mice given three
exposures of 500 radiation-attenuated cercariae 4 weeks
apart via the shaved abdomen, sampled 4 weeks after the last
exposure. Infection serum (I) came from mice exposed to 500
normal cercariae via the same route, also sampled at 4 weeks,
before the start of egg deposition. Control serum came from
uninfected sentinel mice kept under the same conditions as the
test mice for the duration of the experiment. Three pools of
vaccinated and infected serum, each from three mice
(equalized by final worm burden), and two samples of
control serum were analyzed. The 3x vaccinated mice
showed a 70% protection against a percutaneous challenge
with 120 normal cercariae (30).
IFNgR KO mice: Three experiments were performed to
generate the sera used for array screening. Mouse maintenance
and breeding, and experimental details of vaccination were
precisely as given in Wilson et al. (36). In experiment MT1,
groups of seven C57Bl/6 and IFNgR KO mice received one, two
or three exposures to 500 radiation-attenuated cercariae via the
shaved abdomen. At 5 weeks after the last exposure the test mice,
along with seven naïve controls for each group, were subjected to
percutaneous challenge with 200 normal cercariae, with worm
burden and % protection determined by portal perfusion
performed 5 weeks later. The levels of schistosome-specific
IgG1 and IgG2a in the sera at various time points were
determined by ELISA with soluble worm proteins as the
coating antigen, as previously described (38). In parallel with
the above, 15 C57Bl/6 and 15 IFNgR KO mice were given three
exposures to 500 attenuated cercariae, and then terminally bled
14 days after the last exposure to provide serum for a passive
transfer experiment (MT1). The ability of the serum to confer
protection on groups of five naïve recipient C57Bl/6 mice was
tested by administration of 400 µl of immune serum, or control
serum from naïve mice, via the tail vein on two days after
percutaneous challenge via the shaved abdomen, with 200
normal cercariae. Worm burden was determined as above, 5
weeks after challenge, and % protection conferred by
administration of immune relative to naïve serum was
calculated. Two further passive transfer experiments, MT2 and
MT3, were then performed with serum collected from groups of
IFNgR KO mice only, 2 weeks after the third vaccination (the G
sera). Days for administration of donor serum to naïve recipients
were chosen to pinpoint which larval stage was vulnerable to
antibody-mediated elimination mechanisms.
Array Design
Peptide arrays were designed in consultation with PEPperPRINT
(Heidelberg, Germany https://www.pepperprint.com/) and
printed on glass slides using overlapping 15mer peptides, with
a one, two or three amino acid offset, depending primarily on
protein size. In total, we were able to print the sequences of 55
alimentary tract and tegument proteins, exposed at or secreted
from the intra-mammalian stages, which comprise the major
host-parasite interface. Proteins for inclusion on the four arrays
were selected on the basis of our own studies of the worm
transcriptome and proteome, reinforced by whole mount in-situ
hybridization and immuno-localization to confirm tissue of
origin (20, 22, 39–49). In selecting targets we took a
conservative view that secretion, or location on the external
surface of a membrane would be indicated by a signal sequence,
or in a small number of cases (primarily the annexins) there was
evidence from other cell systems for an alternative pathway of
cell egress. The signal peptide was excised since it would not
appear in the mature protein. Regions predicted to be heavily O-
glycosylated were also omitted, the logic being that densely
decorated peptide backbones would not be directly accessible
to immunoglobulins in an infected host. The longest isoform of
MEG proteins was printed; while exon skipping in these proteins
can generate amino acid sequences that might be neo-epitopes,
cost precludes printing all possible combinations. The cellular
origin and list of proteins selected for inclusion is shown in
Figure 1; the sequences printed and their full Smp designations
are given in Supplementary Figure 1. Array 1 comprised 2329
unique peptides from 15 short alimentary tract proteins. For
MEG-4.1, the known heavily glycosylated repeat central region
(40) was omitted. Array 2 comprised 2,089 peptides from 14
longer alimentary tract proteins, with the predicted central
glycosylated region of LAMP-1 omitted. Array 3 comprised
1914 peptides from 20 short tegument surface proteins and
Array 4, 1,913 peptides from six longer tegument surface
proteins. Only the external loops of the two tetraspanins,
aquaporin and SGTP4 were printed. All proteins were printed
in duplicate as overlapping 15mers. Quality control peptides,
po l io marker (KEVPALTAVETGAT) and HA tag
(YPYDVPDYAG) were printed around the periphery. Each
slide was printed with two copies of an array for incubation in
a 3 x 2 well incubation tray. The arrangement of peptides on each
of the four arrays can be seen from the row and column
coordinates on the four pages of the spreadsheet in
Supplementary Table 1.
Array Screening
Peptide Microarrays were screened exactly as described in Li et al
(35); see Supplementary Figure 2 for a flow chart. Mouse
primary antibodies were applied at a 1:200 dilution
throughout. Their binding was detected using Cy3 labeled
Goat anti-mouse IgG (H+L), at 1:300 dilution (A10521,
Thermo Fisher (Cramlington, Newcastle, UK). The two quality
control antibodies provided by PEPperPRINT, pre-labeled with
Cy3 (Po l io ; KEVPALTAVETGAT) and Cy5 (HA;
YPYDVPDYAG), were used at 1:1000 dilution. Two arrays per
slide were each treated with 400µl (300µl for PEPperPRINT
controls) of the appropriate solutions per well, with slow orbital
shaking. Blocking, secondary antibody and control antibody
solutions were each incubated at room temperature for 30 min;
primary antibody solutions were incubated overnight at 4°C.
Arrays were scanned using an Agilent DNAMicro Array scanner
with High-Resolution SureScan Technology (Agilent
Technologies LDA UK Limited, Stockport, Cheshire; model
Farias et al. Epitope Mapping of Schistosome Vaccine Targets
Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 11 | Article 6246133
G2565CA). The instrument has a dynamic range > four orders of
magnitude; by optimizing antibody dilutions the arrays were
never saturated while weaker reactivities were still captured. A
screengrab of the Agilent image was taken for orientation and
editing purposes.
Data Analysis
The Agilent.tif file output for each array was analyzed using the
PepSlide® Analyzer (PSA) software as previously described (35).
Heatmaps were then made from the cell scores for each array to
facilitate visual interpretations. As the same Cy3-Rabbit anti-
mouse detection reagent was used throughout, the mean PSA
scores for each position on the array allow comparisons of the
intensity of reactive regions between individual samples. PSA
scores were color-coded on a linear scale using the Conditional
Formatting function in Excel to highlight reactive regions and
facilitate comparisons between samples. The within-group and
all-group means for each 15mer peptide were calculated. An
aggregate score for each reactive region was determined by
summing adjacent peptide means above a predetermined
threshold, down the array. In turn these aggregates were
combined to give a reactivity score for each of the 55 proteins
under investigation.
Mapping Reactive Regions to 3D
Protein Structures
A total of 26 crystal structures with sufficient sequence
homology to array proteins was identified in the RCSB
Protein Data Bank (https://www.rcsb.org/). To provide
additional criteria for selection as vaccine candidates, we
mapped the reactive regions of each protein onto the 3D
crystal structure using CCP4mg software (50; http://www.
ccp4.ac.uk/MG/). It should be noted that four of these were
S. mansoni structures and the remaining 22 were the nearest
homologues on PDB. A degree of homology between each
array peptide and its protein subject was required for
successful mapping to a crystal structure; the few instances
where an antigenic peptide failed to map are indicated in the
summary table (Supplementary Table 3). Short regions of
reactivity could be mapped directly, while longer regions were
arbitrarily segregated into short runs of ~ nine amino acids, the
number being derived from our previous work mapping
antibodies raised against 15mer synthetic peptides to predict
epitope length (40). Where present, inhibitors/substrates were
displayed in the active site of enzymes, with atoms colored
using a modified CPK (Corey/Pauling/Koltan) scale, to
indicate the location, while the side chains of amino acids
comprising the active site were highlighted as cylinders.
Regions of reactivity identified by the array screen were
displayed on the crystal structure as “worms”, which were
colored by solvent accessibility from blue (buried residue) to
red (accessible residue). This parameter provides a calculated
estimate of amino acid residue accessibility, indicating its likely
exposure for antibody binding in the correctly folded native
protein. No MEG protein structures have been solved but for
members of MEG 3, 4 and 8 families, conserved regions were
aligned using Clustal Omega (https://www.ebi.ac.uk/Tools/
msa/clustalo/) on the assumption that these represented
points of interaction with host macromolecules, which might
make suitable antibody targets. The reactive regions of these
eight MEGs on the array were then mapped to their respective
aligned sequences.
FIGURE 1 | Diagram showing tissues where proteins printed on the array originate and the list of proteins in each category. These tissues represent the major
parasite-host interface where antigens are exposed or released into the blood stream.
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RESULTS
Serum From IFNgR KO Mice Confers
Passive Protection Against Migrating
Schistosomula
The protective immunity and associated specific IgG in C57Bl/6
and IFNgR KO mice induced by one, two or three exposures to
attenuated cercariae, showed markedly different profiles (Figure
2A). For C57Bl/6 mice a single vaccination induced 56.5%
protection, increasing to 73.5% after two exposures with no
further rise after three (72.6%). In contrast, the rise in
protection in IFNgR KO mice was almost linear with the
number of exposures (28 to 40 to 57%), but not to such a high
maximum. In both groups of mice schistosome-specific IgG1 was
the major isotype produced, with only low levels of IgG2a (data
not shown) (Figure 2B). However, at all sampling times the anti-
schistosome titer in the IFNgR KO mice was about 2.5 times
higher than in C57Bl/6 mice. The potency of the 3x vaccine sera
from the two mouse groups was compared directly by
administration to naïve recipients at Days 0 and 3 after
cercarial challenge. The C57Bl/6 donors conferred 28% passive
protection versus 59% for the IFNgR KO donors, corresponding
to the differential antibody titers (Figure 2C, MT1). In the two
subsequent passive transfer experiments with IFNgR KO mouse
donors only (Figure 2C; MT2 and MT3), the serum
administered at Days 0 and 3 conferred 54.9% and 45.7%
protection against cercarial challenge, respectively. The same
sera administered on days 3 and 6 gave reduced protection of
44.5% (MT2) and when administered on days 6 and 9, only 21%
(MT3). We interpret these data to mean that the targets of the
antibody-mediated passive protection are the early stage
schistosomula undergoing migration through the lungs.
Proteins From the Alimentary Tract
Are More Reactive Than Those
From the Tegument
The full dataset obtained from screening the four arrays using the
various sera is available in Supplementary Table 1 and presented
in Supplementary Figure 3 as a series of color coded heatmaps
to indicate the intensity of IgG binding against each 15mer
peptide. In the text, the group means are illustrated to simplify
description of the overall patterns of reactivity (Figure 3). The
highest array cell score was ~40,000 units for the tegument arrays
(Sm25) and ~50,000 for the alimentary tract (calumenin)
A B
C
FIGURE 2 | Properties of sera from IFNgR KO mouse used to screen the arrays. (A) Percent protection of C57Bl/6 versus IFNgR KO mice given one, two or
three vaccinations with 500 radiation-attenuated cercariae and then challenged 5 weeks later with 200 normal cercariae. (B) Antigen specific IgG1 antibody
levels in sera recovered from these mice 14 days after each vaccination. (C) Passive protection against a 200 cercarial percutaneous challenge of naïve C57Bl/6
recipients given injections of serum recovered from 3x vaccinated C57Bl/6 or IFNgR KO mice on the designated days. MT2 and MT3 sera were used to screen
the four peptide arrays.
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(Supplementary Table 1). The number of neighboring reactive
15mer peptides ranged up to 20 for a few proteins (e.g. MEG-4.2,
MEG-8.2) and even 25 for calumenin, but was mostly smaller, in
many cases likely representing a single epitope (Supplementary
Table 1). Inspection of the heatmaps (Figure 3) reveals
considerable variation in the intensity of reactivity of the three
different groups of sera, between the four arrays. Overall, Array 1
comprising short gastrodermal carrier proteins and esophageal
secreted MEGs, shows the strongest reactivity while Array 2,
comprising largely gastrodermal enzymes, is less intense. With a
few exceptions, the short tegumental proteins on Array 3 are
even less reactive (note PSA score), and the long tegumental
proteins on Array 4 show the weakest response of all.
Unsurprisingly, the high titre sera obtained from 3x vaccinated
IFNgR KO mice (G) show markedly stronger reactivity than
those from the similarly exposed C57Bl/6 mice (V), especially on
arrays 1, 3 and 4. A surprising feature of the reactivity is that
although we used genetically inbred mice, there is significant
within-group variation in response to array peptides. The short
alimentary tract protein MEG-8.2 provides an example, with a
broad region of reactivity recognized by all eight sera
(Supplementary Table 1, row 40, col 44-61) versus a
neighboring set of peptides that strongly binds only infection
serum 1 (Supplementary Table 1, row 42 col 7-11).
Esophageal MEGs and Intestinal
Transporters Show the Greatest Reactivity
With IFNgR KO Sera
The complexity of data presented in the heatmaps was further
reduced by summing the reactive regions within each protein
(Supplementary Table 2) and plotting them in a bar chart
(Figure 4). Viewed together, the heatmap (Figure 3) and bar
chart (Figure 4) permit the proteins in each tissue of origin
(Figure 1) to be graded by their overall reactivity. MEG-4.2 was
the most reactive esophageal secretion followed by MEGs 8.1 and
8.2, all in rank order G>I>V (i.e. sera from Vaccinated IFNgR
KO>Infected>Vaccinated mice). MEG-4.1 N and C termini, and
MEG-8.3 were similarly detected most strongly by G sera. MEGs
12 and 15 reacted more strongly with I and V than G sera, while
MEG-9 and VAL-7 were the weakest reactors. However, these
last four proteins reacted primarily at a single region; for MEG-
12 this was at the extreme N terminus and for VAL-7, the C
terminus. MEG-22 also has a single N-terminal reactive region,
most notable in the G sera.
FIGURE 3 | Heatmaps of the mean reactivities of murine serum pools against the peptide arrays: 1) short alimentary tract; 2) longer alimentary tract; 3) short
tegument surface; 4) long tegument surface. V, mean of three C57Bl/6 samples from mice vaccinated with three exposures of 500 radiation-attenuated cercariae. G,
mean of two IFNgR KO samples, MT2 and MT3 passive transfer experiments. I, mean of three C57Bl/6 samples from mice exposed to 500 normal cercariae for 4
weeks. x, mean of all eight pools.
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The transporter proteins secreted from the gastrodermis were
also strongly reactive, especially the putative calcium transporter
calumenin, followed by apoferritin, saposins 1, and 5, in rank
serum order G>I>V. The remaining saposins 2, 3, 4 and 6 were
similarly preferentially reactive with the G sera, whilst ferritin 2
was most reactive against the I sera. The one exception among
the transporters was the Nieman-Pick 2 (NPC2) cholesterol
transporter, only weakly detected by the three groups. It is
notable that the sentinel mice also showed a moderate reaction
to calumenin (Figure 4), potentially implying a pre-sensitization
by some other agent. The gastrodermal secreted proteases,
cathepsin B1, B2, S and L were all reactive over multiple
regions of their sequences at roughly equal strength for G, V
and I sera, but asparaginyl endopeptidase was most reactive with
FIGURE 4 | Bar chart summarizing the reactivity of all proteins on the four arrays, based on the data in Supplementary Table 2. The y axis is cumulative Agilent
peptide score above zero, ignoring protein length for each protein. The means of three I, three V, and two G results are plotted plus one control serum. Note the
much weaker response of tegument compared to alimentary tract proteins (y axis range).
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the I sera. In contrast, cathepsin D was immunologically
unreactive with all sera. The glycosyl hydrolase, beta xylosidase
and the DNAse were moderately reactive against all sera, the
former most so with the G sera. Lastly, the C terminus of
lysosomal associated membrane protein, LAMP-1, was weakly
reactive with all groups.
Few Tegument Proteins Show
Marked Reactivity
The tegument proteins are harder to segregate into functional
groups as many constituents have only been tentatively assigned
to the plasma membrane or its overlying membranocalyx (43).
The most prominent reactive protein, especially with G sera, was
Sm25 of unknown location and function. Among potential
membranocalyx constituents Sm200, Sm29, Sm13, and TSP-2,
only Sm200 was reactive, particularly with G sera, while the
others were weakly detected with I sera. The reactivity of GPI-
anchored tegument enzymes, ADP-ribosyl cyclase and carbonic
anhydrase, on the outer leaflet of the plasma membrane, were
notable, greatest for G sera in the former, and for I and V sera in
the latter. In contrast, GPI-anchored alkaline phosphatase and
CD59 Smp_015390 were virtually silent; only CD59
Smp_105220 showed weak reactivity. Membrane-spanning
apyrase (ATP-diphosphohydrolase), with a large extracellular
domain, reacted only with G sera, while the external loops of the
membrane transporters aquaporin and SGTP4 were virtually
silent. The tegumental enzyme calpain showed moderate
reactivity, especially with I sera. The three annexins and
tetraspanin Smp_194970 loop likely play a membrane
structural role, and all were weakly reactive with I sera. There
are four tegument-associated MEGs, but only MEG-24 showed
weak reactivity with all three sera. Finally, the three members of
the MEG-3 family, expressed in the schistosomular tegument
and head gland, reacted principally with I sera, in rank order
MEG-3.1>3,2>3.3.
Normalizing by Amino Acid Content Allows
Ranking of Protein Reactivity by Size
The proteins printed on the four arrays differ in size from 8 to
200 kDa, and the divergence was normalized to create an index
by dividing the mean reactivity score (Supplementary Table 2)
by the total number of amino acids in the printed protein. The
indexes, displayed as a scatter plot (Figure 5), and sorted by
tissue of origin, segregated into four distinct but overlapping
groups. Based on amino acid content (AA) the esophageal
MEGs + VAL-7 are the smallest alimentary tract proteins (x
100 AA), followed by gut carriers + LAMP (x 166 AA) and
finally hydrolases (x 414 AA); the 17 tegument proteins
range between 44 and 1630 AAs (x 262 AA, skewed by Sm200;
median = 129 AA). The mean reactivity values for each
functional group show the esophageal MEGs lying at the top
left (x 3285 +/- S.E. 827), the gastrodermal carriers in the center
(x 2689 +/- S.E. 427), and the gastrodermal enzymes to the right
(x 1249 +/- S.E. 187). All means are significantly greater than the
tegument proteins (x 625 +/- S.E. 155; P<0.001 for MEGs and
carriers, P<0.05 for enzymes), distributed along the bottom of the
plot; the carriers are significantly different from the enzymes
(P<0.05) but not the MEGs. Taking the tegument proteins as
unity, the esophageal MEGs are 5.25x, the carriers 4.31x and the
gastrodermal enzymes 2.0x more reactive with the murine
IgG samples.
Mapping the Reactive Regions to
Protein Structures Reveals the
Location of IgG Binding Sites
The final step in the mapping process was to use 3D crystal
models of the native molecule to identify which regions in the
most reactive proteins were likely to be accessible to antibodies,
and hence were likely to have the potential for neutralization of
function and/or formation of insoluble immune complexes. We
elected to map the strongest reactive region in each instance,
rather than mean values across the array, so that all potential
epitopes were covered, even if detected by only one serum
sample. To avoid repetition in the text, the full data set of
antigenic peptides, extracted from Supplementary Table 1, is
tabulated by individual protein as Supplementary Table 3,
which also gives the number of sera in which a reactive region
was found, the aggregate PSA score of the region, and pertinent
comments on crystal location. Six representative structures are
illustrated in Figure 6 and the full set of 26 mapped proteins is
presented in Supplementary Figure 4 with a color key and
additional commentary where necessary. The two best peptides
selected for all antigenic proteins, mapped or otherwise, are
presented in Table 1.
Gastrodermal Enzymes
For enzymes, the ideal antigenic peptide would be accessible,
include an amino acid involved in substrate binding, and have a
high aggregate PSA score. When the reactive regions of the
FIGURE 5 | The mean reactivity of array proteins based on the data in
Supplementary Table 2, normalized for number of amino acids and
segregated into four groups by tissue of origin. The differences in group
reactivity were tested for significance using a t-test. Note the log y axis scale.
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gastrodermal secreted cathepsins B1.2, B2, L and S plus
asparaginyl endopeptidase (Supplementary Table 3) were all
successfully mapped, these conditions were rarely fulfilled. The
antigenic regions lay in external loops and a helixes, while the
color gradations on the models indicate that some epitopes were
buried and unlikely to be accessible to IgG in the native folded
state. The mapping to the crystal structure of asparaginyl
endopeptidase (Figure 6A) provides a worked example. The
color-coded reactivity of all eight sera plus the control, against
the sequential 15mer peptides of the enzyme, with a two amino
acid offset, are shown in Supplementary Table 3, page 1. Moving
down the array, the most reactive region is copied over to the
Aggregate column and its aggregate PSA score calculated. The
15mer peptide that best represents the center of the region is then
selected, and the core 8-10 amino acids highlighted for mapping
to the crystal structure. For asparaginyl endopeptidase there are
16 distinct regions, but P1 is not in the crystal structure. When
the remainder are mapped onto the crystal, the color range runs
from accessible red to buried blue. Thus, P10 contains the
cysteine that forms part of the active site but has the lowest
aggregate score (26107), and a blue/purple color so is unlikely to
be accessible to antibody (Figure 6A). P5 (164692) and P9
(170611) in external loops had the highest PSA scores but
present a dilemma; both are reactive only with infection serum
(pool I3). We therefore chose P7 (88288), reactive with both G
sera, so potentially involved in protection. A second possibility
presented itself in the mapping of the asparaginyl endopeptidase
regions to a different crystal model containing the pre-protein
(Supplementary Figure 4.8). Here, P13 (78797) mapped to the
alpha cleavage site so binding of antibody there could potentially
interfere with protein activation. The downside is that this region
was only weakly reactive with the two G sera.
Similar considerations were applied to the other gastrodermal
proteases. P10 of cathepsin S encompassing the S2 substrate
pocket, detected by almost all sera, had the lowest score out of 15
peptides (Supplementary Table 3). The next best situation
would be a region where antibody binding in proximity, might
block the active site. P4 of cathepsin B1.2 is the best example in
an accessible loop close to the site, with a good PSA score (Figure
6B). Interference with activation is also feasible for other
proteases. Thus, the junction with the propeptide in cathepsin
L at P7, was antigenic and accessible. Finally, P12 encompassing
the occluding loop of cathepsin B2, which regulates active site
function, was strongly antigenic and surface accessible. The
remaining peptides selected for the above five proteases were
loop structures chosen for their accessibility and high PSA score.
Gastrodermal Carrier Proteins
Apart from calumenin, all the gastrodermal secreted ferritins,
saposins, and NPC2 were mapped to crystal structures
(Supplementary Figure 4). The nanocage of ferritins,
comprising 24 units each composed of four a-helix bundles,
has a complex structure with eight entry channels admitting Fe2+
ions to 24 ferroxidases via transit sites for conversion to the
stable Fe3+ state (see Supplementary Figure 4.9). Apoferritin is
strongly antigenic along segments of the helixes; Peptides 4, 5,
and 9 encompass the ferroxidase and P8 the transit site, but
many of the relevant amino acids are on the internal surface
of the helixes, so potentially inaccessible in the intact cage
(Figure 6C). The most obvious targets on apoferritin are the
P4 ferroxidase and P15 entry channels, with high PSA scores,
where antibody binding might disrupt function (Supplementary
Table 3). The situation is similar with Ferritin 2, where P10
encompasses the ferroxidase site and P17 an entry channel
(Supplementary Table 3). The schistosome saposins possess a
domain (two in Sap 6) comprising four a helixes separated by
two hinges and a loop. They combine in pairs, unfolding to create
a lipid-transporting disc (Supplementary Figure 4.12). Reactive
regions were located in the helixes of all six mapped structures
but the hinges and loop appeared the most accessible, with a high
PSA score. For saposins 1-5 it was possible to select a hinge-loop
combination of peptides and for saposin 6, hinge 1 and helix 1
peptides. NPC-2 binds cholesterol in a deep hydrophobic pocket
sandwiched between the two b-sheets, its entry being regulated
by an apolar rim (Supplementary Figure 4.19). The protein was
poorly reactive with all sera, but P2 with the lowest score,
encompasses two amino acids in the apolar rim, while P4 is an
accessible loop (Supplementary Table 3). Lastly in this group,
the LAMP-1 protein mapped only poorly to the available crystal
structure (Supplementary Figure 4.30); the P2 and P5 surface
loop/b strands of the C-terminal b-prism fold structure were
selected as targets.
Tegumental Proteins
Four tegumental enzymes were mapped, calpain with 22 regions
being the most reactive, although only half were in the crystal
model. Residues in the active site were not reactive, so high
scoring accessible loops P3 and P13, the latter comprising one of
the two Ca2+ binding sites involved in activation, were selected
(Figure 6D). For carbonic anhydrase (a S. mansoni crystal), two
histidines of the catalytic site and the Zn2+ binding location were
present within P4 and P7 but both regions were buried (blue)
within the hollow core of the protein (Figure 6E). Therefore, two
surface loops, P3 and P9, were selected, being detected by most
sera (Supplementary Table 3). ADP ribosyl cyclase presents a
similar dilemma since it functions as a homodimer on the
membrane with the two catalytic sites apposed, so although P6
with active site glutamine residue and P7 substrate interaction
site were reactive (but low PSA score), they may not be accessible
in situ. Two loops comprising P1 and P2, recognized by all sera
and distal to the membrane anchor, were therefore selected
(Supplementary Table 3; Supplementary Figure 4.21). The
external domain of apyrase was detected predominantly only
by G sera. The catalytic site was immunologically silent so the P2
loop and P7 short helix were selected, based on PSA score
(Supplementary Table 3).
The two tetraspanins and three annexins, all relatively
unreactive especially with G sera, were mapped to crystals. For
TSP-2 (another S. mansoni crystal), the high-scoring P6 loop and
the partially buried P5 loop were selected, while for TSP
Smp_194970 P3 and P4 were selected, even though they were
partially or completely helical structures, respectively. The
situation with the three annexins is more complex; they
contain multiple binding sites for Ca2+ ions on the convex
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surface, involved in interaction with membrane phospholipids.
For annexin Smp_074150 (another S. mansoni crystal structure),
all PSA scores were low; P9 encompassed one of the six Ca2+ sites
but this annexin is another example of a disulphide-linked
apposed homodimer (Supplementary Figure 4.26) so the
peptide may not be accessible in situ. The exposed P1 loop was
chosen as the second target. Annexin Smp_074140 with few
reactive regions, lacks the dimerizing cysteine and the P5 Ca2+
binding site may be accessible. In addition, although P3 is part of
a helix, it incorporates a membrane interaction site, so antibody
binding could block function. Annexin Smp_077720 had more
reactive regions, with helical P6 containing the membrane
binding site but also the lowest PSA score of 10 peptides; the
two calcium binding loops in P4 and P8 were therefore selected.
The tegument surface GPI-anchored protein CD59,
Smp_105220, was only weakly reactive with I sera; P3 and P4
were selected, part loop-helix and part loop-b strand,
respectively, based on projected accessibility.
Esophageal Secreted Proteins
Among esophageal secreted proteins only VAL-7 could be
mapped to the crystal structure of schistosome VAL-4 (Figure
6F). It was notable that both its caveolin motif and CAP domain
were largely immunologically silent. However, all sera recognized
P6, an exposed loop at the C-terminus, complemented by P3
adjacent to the CAP site. The esophageal MEGs lack homologous
crystal structures but the conserved sequence of MEGs 4.1 and





FIGURE 6 | Reactive regions mapped onto six selected crystal structures using CCP4mg (50). (A) Aspariginyl endopeptidase. (B) Cathepsin B1. (C) Apoferritin.
(D) Calpain. (E) Carbonic anhydrase. (F) VAL-7. The protein chain is colored ice-blue in ribbon format. The position of each reactive region listed in Supplementary
Table 3 is shown in worm format and selected key peptides from Table 1 or Supplementary Table 3 are indicated by P number. The worms are colored by
solvent accessibility ranging from buried (blue) to accessible (red) on a scale 0-200 Å2, based on the algorithm described by Lee and Richards (51); the detailed key
for each model is illustrated in Supplementary Figure 4. Where present, inhibitors/substrates are displayed in the active site of enzymes in ball and stick format,
with atoms colored using a modified Corey/Pauling/Koltan (CPK) convention, to indicate their location, while the side chains of amino acids comprising the active site
or other named features are highlighted as cylinders.
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domain) can be exploited to select peptides (Supplementary
Table 3 and Supplementary Figure 5). For MEG-4.1 the highly
reactive peptides, N terminal P1 and C terminal P2 were selected,
and for MEG-4.2 highly reactive P4 and reactive, conserved P8.
A similar situation pertains with the three MEG-8 isoforms (18%
identical and 52% conserved residues), with all three variants
showing strong binding of sera in the conserved region
Supplementary Table 3 and Supplementary Figure 5), from
where peptides were selected. The three members of the MEG-3
family, expressed in the schistosomular head gland and tegument
(55% identical, 77% conserved residues) contain seven pairs of
cysteines, separated by three amino acids, and spaced 9–12
amino acids apart, throughout each sequence, implying a rigid
and highly organized structure (Supplementary Figure 5). With
one exception at the C terminus of MEG-3.1, especially in I
samples (Supplementary Table 3), the aggregate scores of
reactive regions are weak. Nevertheless, aligned peptides can be
selected in proximity to the N and C termini of all three proteins.
Unmapped Proteins
No structural mapping or sequence analysis proved possible for
three gastrodermal secretions (b-xylosidase, DNAse, calumenin),
four esophageal MEGs (9, 12, 15, 22) and four tegument surface
proteins (Sm13, Sm25, Sm200, MEG-24). The only criteria for
selecting peptides were their PSA score and extent of reactivity
with the eight screening sera (Table 1). Sm25 was notable for
TABLE 1 | Principal Reactive Epitopes.
Protein * Peptide 1 Why chosen Peptide 2 Why chosen
Cathepsin B1.2 G P4 ESCGLGCEGGILGPA active site P10 KAQKEIMKYGPVEAS loop
Cathepsin B2 G P12 TTNGCQPYEFPPCEHH occluding loop P15 NGPVEVDFEVYADFP beta sheet-loop
Cathepsin L G P7 ELSNDPLPSKWDWRD junction propep P12 SSCHFRKSKGVVKVK loop
Cathepsin S G P10 DHECVENPVSVAFDF active site P13 SGVLLIDDCQNEEPF loop
Asp endopep G P7 TDHGAPGLIAFPDDE loop P13 VSEFQGSRDKSSTEN a cleavage site
Apoferritin G P4 QILNEYEAFYIYDHM ferroxidase P15 NDATTQDFLDDFLQE Fe entry channel
Ferritin 2 G P10 EFFRKASHEEREHAE ferroxidase P17 LTDFIESQYLHEQED Fe entry channel
Saposin 1 G P5 GRLIKIFLEDEPFIP hinge 1 P8 CKLIPERHWRNECLD loop
Saposin 2 G P4 SLAHYFMDDLYWRDV hinge 1 P8 EVGSLIGPGICTDFD hinge 2-helix 4
Saposin 3 G P3 ICSLTGSFEVQCSFL loop P6 MFIDKYIDTISTMDP hinge 2
Saposin 4 G P2 WQTYLNSTSVDEKIE hinge 1 P5 YFFFRYRCEEFMERY loop-helix 3
Saposin 5 G P3 RGIRWLLLQSYTRKT hinge 1 P8 HDFVVNMSVYEPCQY hinge 2-helix 4
Saposin 6 G P3 GMNLVHYILSEDYWV helix 1 P4 HYILSEDYWVKIYMI hinge 1
Nieman-Pick 2 G P2 VPIPFALDNSNLCEF apolar rim P4 WELQDSSNEDIVCVE loop
LAMP-1C G P2 LSNATINDNESVCSE loop-beta strand P5 IPVGSYYSCLTVPEI loop-beta strand
Calumenin G P1 LETVSRRDTEHFADD v immunogenic P17 STPFDENEPEPEWVE v immunogenic
b Xylosidase G P4 LSFEADVPEHDLWMT v immunogenic P12 IGMWGTDIDEGYWWI v immunogenic
DNAse G P4 KWTKPLGYDRENLWW v immunogenic P7 LNHFSKSSDFGKDLY v immunogenic
Apyrase T P2 RLKLIEDPLGSLDLF loop P7 LQGYKSDLYNAFEWF short helix
ADP Ribosyl cyc T P1 NISCSEIWNSFESIL helix P2 KSACVMKSGLFDDFV loop
Carb anhydrase T P3 TWFISFDGILDYKYE loop P9 MHQIVESIKYEQTAF loop
Calpain T P3 TERTLWEDPDFPAND loop P13 LSFTADGEFWMSYED Ca2+ binding
TSP-2 T P5 QQKLHCCGADSPKDY loop P6 KDYGENPPTSCSKDG loop
TSP-194970 T P3 QYYEKHPNYENQVDN loop-helix P4 PNYENQVDNLQREFF helix
Annexin 074150 T P1 RSLIHSFDPHGKHYR loop P9 KSLLNAVKDDTSGDY helix-Ca binding
Annexin 074140 T P3 MSQVEQDVEILWDAG lipid binding P5 EDWIRNETSGDYQRL loop-Ca binding
Annexin 077720 T P4 LESDIIKETKPPYEQ loop-Ca binding P8 LYDSMYGLGTREDTL loop-Ca binding
CD59 105220 T P3 IAKDCVASCVPQDRR loop helix P4 GGKAGLVTECCDEDY loop beta strand
Sm13 T P1 EPEPEPEPVPVSRNS v immunogenic none
Sm25 T P1 NSNSIITDEDYDHYN v immunogenic P2 FHRNSDPDGFPEYEF v immunogenic
Sm200 T P13 CRPTYLLLEFIEPNI v immunogenic P16 PGRRYELQAEVIYTE v immunogenic
VAL-7 E P3 CVPRRSNMTMRKGSK loop-Cap site P6 KYANRQPYDPIYPED loop
MEG-4.1 E P1 PLDDRFNDVNTIN N terminus P2 PLYYMVEKFVQIMGY conserved C-term
MEG-4.2 E P4 NHNKFHEMPEYDDQL v immunogenic P8 PLWLVNPIYYVLELF conserved C-term
MEG-8.1 E P7 GDGFFDLFSEQEFHP imm & conserv P9 KSYLFNFWYLFRTSF conserved
MEG-8.2 E P7 KFNSIFGEEEYNPPK imm & conserv P8 EYNPPKDSDFTERLW imm & conserv
MEG-8.3 E P2 FNPPKESEFYERFWE conserved P3 FYERFWELFKHCFLN conserved
MEG-9 E P2 SSTEGQNHEESQFFL immunogenic P4 AHFLQFLNGCFLNMD immunogenic
MEG-12 E P1 ENYEQQLQQP v immunogenic P2 QQLQQPKAYGIWSLF v immunogenic
MEG-15 E P2 LSHHNTVPAKTTRKS immunogenic P5 IPQIKTIEFSQNENL immunogenic
MEG-22 E P1 GSPVPHPSVYFDNPE N terminus none
MEG-3.1 S P1 AERECKKHCEGNNEY conserved P6 GSFPLCLYNCDQEHP conserved
MEG-3.2 S P1 TQQECVRHCGGHNEY conserved P5 LYNCDQGNGSGNFDE conserved
MEG-3.3 S P1 QQECEKNCKGDNEYV conserved P2 TDPRKDGADGSEDFD conserved
*Tissue of origin: G, Gastrodermis; T, Tegument; E, Esophageal glands; S, Lung schistosomulum.
Pairs of peptides selected from the 44 reactive proteins detected on the arrays, based on their aggregate score, and accessibility indicated by mapping to crystal structures.
Amino acids in red are predicted epitopes.
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being one of the most reactive proteins in the whole screen with
very high PSA scores (Figures 3, 4). Tegumental Sm13 and
MEG-24 possess reactive and presumably accessible N-termini;
Sm13 has only one reactive region (See Table 1). Esophageal
MEG-12, one of the few known products of the of the anterior
esophageal gland, has a similarly highly reactive N-terminus. The
remaining proteins are tabulated without comment. As if to
emphasize the low reactivity of tegument proteins, nine of the ten
array subjects that failed to provide any antigenic information
have an authenticated tegument surface location.
DISCUSSION
Antibodies Mediate Protection After
Vaccination of IFNgR KO Mice
A single exposure of C57Bl/6 mice to the RA schistosome vaccine
elicits a strong Th1 response operating against challenge
schistosomula in the lungs by blocking their onward migration
and deflecting them into the alveoli (8, 9, 52). Further exposures
to the vaccine increase the humoral component of protection
(53) with the higher levels of antibody generated being able to
confer protection passively on naïve recipients [(54) and the
current data]. Conversely, IFNgR KO mice lacking the cell
mediated arm of the immune response, are poorly protected by
single exposure (36) but we show here that when such mice are
given multiple exposures the level of protection increases in
proportion to IgG1 titer. Pertinent to epitope mapping, these sera
conferred a mean of 53% passive protection to naïve mice when
administered on days 0 and 3 of challenge, almost double that of
comparable C57Bl/6 mice. The reduction of protection at later
times indicates either that the lung schistosomulum is a special
immune target or that the act of pulmonary migration is
particularly hazardous. The observations from the systems
biology analysis (30) suggest that the subtle changes induced in
hemostasis, coagulation and chemokine pathways by vaccination
simply make the lungs a more difficult capillary bed to traverse.
Antigenic Load in Infected Versus
Vaccinated Mice
The inclusion of 28-day infection sera in the array screen was
intended as a comparator to determine whether vaccine sera
reacted with any unique targets. A potential limitation of this
comparison is the disparity in antigenic load provided by ~150
pre-adult liver worms with an active gut versus 3 x 500
schistosomula that do not develop beyond the lung stage. The
former are estimated to vomit 5.6 mg of alimentary tract proteins
per day (Leandro Neves, personal communication) versus the
total protein content of 500 lung schistosomula of ~ 20 mg (55)
releasing ~0.2 mg of secretions per day (21). Whether such
heavily infected mice would develop any protection cannot be
assessed, due to the complications of egg-induced pathology and
mortality that would follow patency around day 35. However,
both the absence of protection after challenge of mice with a
single sex infection (56) or chemotherapeutic cure before
pathology develops (57) suggest they would not be protected.
Selection of Proteins
We aimed to be comprehensive in our selection of proteins but
there are some omissions from the target list, including a second
t egumenta l c a lpa in [46 , Smp_137410 , (58 ) ] and
phosphodiesterase 5 (59), based on their MW; the same
criterion applies to the omission of a2 macroglobulin from the
gastrodermis, with a MW ~230kDa. The esophageal glands are
the most underrepresented, MEGs 11, 14, 31.1 and 31.2 being
deliberately omitted as they are anchored in the surface lining
and predicted to be heavily O-glycosylated. Cystatin, MEGs 3.4,
16, 17, and the MEG-26 family, plus two phospholipase A
proteins, several aspartyl proteases and palmitoyl-thioesterase
were also omitted; with the exception of cystatin their transcripts
were of low abundance (41). Most recently several MEG-2 family
members have been identified as differentially expressed in day 6
lung schistosomula (25), which may also be products of the head
gland and tegument.
Epitope Conformation
It is unclear whether the linear 15mer peptides on the arrays take
up any native conformation such as an a-helix. However, the
mapping of reactive regions on the array to crystal structures
revealed antibody binding to a-helixes and b-sheets as well as
extrinsic loops. The ability of the arrays to detect conformational
epitopes, where key amino acids are brought together by protein
folding into tertiary structures, is uncertain. Such structures are
best understood in the context of the rigid capsids of viruses. At
one extreme, the participating amino acid targets of two
neutralizing monoclonals on the surface of human papilloma
virus were widely dispersed throughout the target protein and
even on an adjacent molecule (60). At the other, interaction of
neutralizing antibodies with Hepatitis C virus E1 and E2 surface
glycoproteins revealed epitopes the were largely linear, and the
viruses evaded neutralizing antibodies by mutating amino acids
within the epitope sites (61). The schistosome tegument is more
fluid/flexible than a viral capsid but several surface proteins
contain numerous disulphide bridges, implying a tightly folded
3D structure. The presence of conformational epitopes in Sm29
(18 Cs) the three MEG-3s (16 Cs) and two CD59s (10 Cs) could
well explain their low reactivity with the mouse sera if epitopes
were conformational rather than linear. This argument does not
hold for cathepsin D with six cysteines, fewer than the other
reactive cathepsins, or alkaline phosphatase with four cysteines,
both of which are virtually silent.
The Reactivity of Potential Targets
A more plausible explanation for the low reactivity of array
targets, especially of the tegument proteins, is that they have been
subject to evolutionary pressure by the immune system due to
their exposed location (62). Indeed, it seems highly likely that a
worm living for decades in the bloodstream would require an
unreactive surface to survive and thrive. Adult worms fixed in
situ in both rodents and primates show no evidence of adherent
leucocytes (63) but immunoglobulins and complement factors
have been identified by proteomics in tegument membrane
preparations (20, 46). However, the membrane attack complex
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does not form so the immune evasion mechanisms deployed by
established adult worms are adequate to ensure survival (52). It is
possible that exposed tegument proteins possess conserved
amino acids for interaction with external targets, having
limited possibilities to mutate without loss of function. Epitope
mapping may identify such regions if they are reactive. With the
alimentary tract proteins, there is a different consideration. The
gut lumen is an acidic hydrolytic environment akin the inside of
a lysosome (39). It is unclear whether antibodies can survive in
such a degradative environment to exert a blocking effect on gut
function. The esophageal secretions may be in an intermediate
situation, especially those of the anterior gland, since ingested
blood is at pH 7.4 and must be rapidly acidified, either as it passes
along the esophageal lumen or after entry into the gut lumen.
Thus, there is a possibility that the esophageal secretions make
more plausible immune targets.
Selecting Vaccine Targets
When we evaluate the screened proteins for vaccine potential,
normalized by size, the esophageal secretions are the most highly
immunogenic, especially MEGs 4.1, 4.2, 8.1, and 8.2 from the
posterior gland and the N terminus of MEG-12 from the anterior
gland. It is notable that these same five esophageal proteins were
reactive in the peptide array analysis of host responses to S.
japonicum (35). Their proposed function is to initiate blood
processing in the esophageal lumen (40, 41), and their reactivity
is highest with the protective G sera. In addition, the six saposins
and apoferritin from the gastrodermis have the strongest
reactivity with G sera. Leaving aside the question of antibody
stability, targeting the hinge/loop regions of saposins may be a
good strategy to block lipid-binding. However, at least ten are
encoded in the genome (49) possibly reflecting a degree of
functional redundancy, as an evasion strategy. Conversely,
there is only a single cholesterol transporting NPC2 protein,
but it is a weak antigen. The gastrodermal proteases (Cathepsins
B1.2, B2, S & L) present numerous targets but few epitopes lie
near the active center so there appear to be limited opportunities
for direct blocking of catalysis. There is also the potential for
functional redundancy in the cascade. Prevention of activation
by binding to a protease pre-protein is an alternative strategy,
with asparaginyl endopeptidase as a desirable target since it also
initiates activation of other peptidases (64). Ferritin 2 was
included although it lacks a signal peptide, as it was identified
by proteomic analysis of vomitus (39). Calumenin which was
identified in the same study as a potential calcium transporter,
has a signal peptide but is normally located within the lumen of
the endoplasmic reticulum. On balance, the similarity of the
schistosome gut lumen to the contents of a lysosome make these
two proteins valid constituents of gut secretions, hence potential
targets for a protective response. The screen of tegument proteins
identified a smaller cohort of potential candidates. Calpain was
highly reactive and has been much studied as a single-antigen
vaccine (5). However, the vaccine potential of Sm25, ADP-
ribosyl cyclase and carbonic anhydrase have not been reported.
The reactive N-terminus of Sm13 also deserves attention due to
the alternating proline and glutamic acid residues suggesting a
novel function that might be blocked by antibodies.
Esophageal Gland Secretions
Are Plausible Targets
The reactivity of the sera from vaccinated mice with alimentary
tract proteins has illuminated an unsuspected feature of
schistosome physiology. Feeding on erythrocytes, and worm
growth, only begins after arrival in the portal distributaries of
the liver (44, 55) so it has been assumed that the larval gut was
non-functional up to that point. However, electron micrographs
of lung schistosomula in vivo show the gut lumen packed with
granular material (10). The strong reactivity of the protective G
group sera with esophageal MEGs and gastrodermal saposins
indicates that both tissues are productive at the lung worm stage,
although ingestion of erythrocytes is not occurring. This widens
the scope of targets mediating elimination of challenge parasites
in the lungs. Supporting evidence for the synthetic activity of the
esophageal glands and gastrodermis has come from the recent
publication of a transcript screen of the intra-mammalian stages
(25). Scrutiny of transcript abundance in day 6 ex vivo lung
worms revealed MEG-15 as the most abundant, while MEG-9,
MEG-4.2, two saposins and two cathepsins were all in the top 30
most highly expressed transcripts out of ~10,600 genes
interrogated (Supplementary Figure 6). In day 28 liver worms
the intensity of expression of alimentary tract proteins was no
longer quite so dominant but there were still eight representative
genes in the top 100 transcripts (Supplementary Figure 6).
Applications to Vaccine Development
How best might the information accumulated in this study be
used to advance vaccine development? The data on protein
reactivity lends itself to the development of monoclonal
antibodies (mAbs) specific for individual epitopes on putative
target proteins. This approach was fashionable 40 years ago but
proved short-lived (see (65) for review). Peptide array screening
allows us to pinpoint the reactive epitopes on individual target
proteins; mAbs could then be generated against those epitopes
using synthetic peptides as targets. They would be useful as
reagents to test hypotheses generated in this study about
blocking activity of antibodies e.g. of enzyme activation by
binding a cleavage site; direct inactivation by binding in or
near an active site; the prevention of lipid uptake by binding
hinge and loop regions of saposins. The mAbs could also be
administered in calibrated doses to infected mice, singly or in
cocktails, to investigate in vivo effects. Although cost
considerations undoubtedly preclude their development for use
as a human schistosome control agent, it is worth noting that a
cocktail of three monoclonal antibodies (REGN-EB3) has been
successfully developed by Regeneron and licensed as a therapy
against Ebola virus (66).
The alternative approach is to perform direct vaccination
experiments, probably initially in the mouse model. Several array
proteins have already been tested singly with varying degrees of
success. They include TSP-2 (67), Sm29 (68), Sm200 (69), and
calpain from the tegument, MEG-4.1 from the esophagus (70),
and cathepsin B1.1 (71), Saposins 4 and 6 (72) from the
gastrodermis. The mouse has limitations as a vaccine screen
for schistosomes (7) but remains the most practical option for
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large scale testing. Individual proteins here highlighted could be
tested singly (e.g. tegumental Sm25 or esophageal MEG-4.2).
However, finding an Achilles heel in the form of a single magic
bullet for a schistosome vaccine, whilst highly desirable, seems
implausible in a complex and sophisticated blood-dwelling
parasite. Therefore, we advocate an alternative approach
whereby the coding regions of reactive epitopes are combined
in a string-of-pearls synthetic gene. Expression of these genes as
recombinant proteins in quantity would allow multiple proteins
to be targeted simultaneously. As proof of principle we have
already tested the approach in our analysis of the reactivity of S.
japonicum esophageal proteins and showed that the majority of
encoded epitopes elicited high titers of antibodies in recipient
rabbits (35). The data from both strong and weak reactor
proteins displayed in Table 1, can be combined into constructs
for expression and vaccination. We suggest that simultaneous
direction of the immune response to multiple targets on, or
released by the migrating lung schistosomulum, will maximize
the host response, so blocking its attempts to traverse the lung
capillary bed.
AUTHOR'S NOTE
The recent publication by Wendt et al. (Science. 2020 Sep 25;369
(6511):1644-1649) has identified Smp_147680 calumenin as
expressed exclusively in muscle cells, suggesting that it is a cell
leakage contaminant of vomitus. This observation would explain
its very high PSA score; as an internal protein it has not been
selected for immunological silence by the immune system.
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